{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:59:25Z","timestamp":1781787565573,"version":"3.54.5"},"reference-count":13,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2015]]},"DOI":"10.1248\/bpb.b15-00323","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T18:03:01Z","timestamp":1436378581000},"page":"1430-1433","source":"Crossref","is-referenced-by-count":16,"title":["Successful Colistin Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa<\/i> Infection Using a Rapid Method for Determination of Colistin in Plasma: Usefulness of Therapeutic Drug Monitoring"],"prefix":"10.1248","volume":"38","author":[{"given":"Takehiro","family":"Yamada","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Infection Control Team, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Infection Control Team, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Oku","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Endocrinology, and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuma","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Endocrinology, and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Endocrinology, and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Endocrinology, and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Infection Control Team, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumio","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Infection Control Team, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Akizawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Furugen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Iseki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital"},{"name":"Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother.<\/i>, 55<\/b>, 3284\u20133294 (2011).","DOI":"10.1128\/AAC.01733-10"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis.<\/i>, 6<\/b>, 589\u2013601 (2006).","DOI":"10.1016\/S1473-3099(06)70580-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Martis N, Leroy S, Blanc V. Colistin in multi-drug resistant Pseudomonas aeruginosa<\/i> blood-stream infections: a narrative review for the clinician. J. Infect.<\/i>, 69<\/b>, 1\u201312 (2014).","DOI":"10.1016\/j.jinf.2014.03.001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa<\/i> infections. Infection<\/i>, 37<\/b>, 461\u2013465 (2009).","DOI":"10.1007\/s15010-009-8342-x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis.<\/i>, 40<\/b>, 1333\u20131341 (2005). Corrected in Clin. Infect. Dis.<\/i> in 2006, 42<\/b>, 1819.","DOI":"10.1086\/429323"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Yaita K, Sameshima I, Takeyama H, Matsuyama S, Nagahara C, Hashiguchi R, Moronaga Y, Tottori N, Komatsu M, Oshiro Y, Yamaguchi Y. Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa<\/i> treated with colistin; a case report and review of the literature. Intern. Med.<\/i>, 52<\/b>, 1407\u20131412 (2013).","DOI":"10.2169\/internalmedicine.52.9296"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Bode-B\u00f6ger SM, Schopp B, Tr\u00f6ger U, Martens-Lobenhoffer J, Kalousis K, Mail\u00e4nder P. Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring. Int. J. Antimicrob. Agents<\/i>, 42<\/b>, 357\u2013360 (2013).","DOI":"10.1016\/j.ijantimicag.2013.06.009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother.<\/i>, 52<\/b>, 987\u2013992 (2003).","DOI":"10.1093\/jac\/dkg468"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob. Agents Chemother.<\/i>, 46<\/b>, 3304\u20133307 (2002).","DOI":"10.1128\/AAC.46.10.3304-3307.2002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Jansson B, Karvanen M, Cars O, Plachouras D, Friberg LE. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC-MS\/MS. J. Pharm. Biomed. Anal.<\/i>, 49<\/b>, 760\u2013767 (2009).","DOI":"10.1016\/j.jpba.2008.12.016"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Mizuyachi K, Hara K, Wakamatsu A, Nohda S, Hirama T. Safety and pharmacokinetic evaluation of intravenous colistin methansulfonate sodium in Japanese healthy male subjects. Curr. Med. Res. Opin.<\/i>, 27<\/b>, 2261\u20132270 (2011). Corrected in Curr. Med. Res. Opin.<\/i>, 2015, 31<\/b>, 593\u2013594.","DOI":"10.1185\/03007995.2011.626557"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Couet W, Gregoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin. Pharmacol. Ther.<\/i>, 89<\/b>, 875\u2013879 (2011).","DOI":"10.1038\/clpt.2011.48"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Sorli L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, \u00c1lvarez-Lerma F, Knobel H, Benito N, Horcajada JP. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect. Dis.<\/i>, 13<\/b>, 380 (2013).","DOI":"10.1186\/1471-2334-13-380"}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/advpub\/0\/advpub_b15-00323\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T11:21:56Z","timestamp":1498216916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/38\/9\/38_b15-00323\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b15-00323","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}